ストックスクリーナーアプリを入手
12.45
1.46%
0.20
前日終値:
$12.25
開ける：
$12.26
24時間の取引高:
338.46K
Relative Volume:
0.30
時価総額：
$621.42M
収益：
-
当期純損益:
$-156.39M
株価収益率:
-3.374
EPS:
-3.69
ネットキャッシュフロー:
$-123.06M
1週間 パフォーマンス:
-2.67%
1か月 パフォーマンス:
-14.40%
6か月 パフォーマンス:
+30.42%
1年 パフォーマンス:
-4.25%
1日の値動き範囲:
$12.19
$12.58
1週間の範囲:
$12.18
$12.87
52週間の値動き範囲:
$7.30
$16.32
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
名前
Kalvista Pharmaceuticals Inc
セクター
電話
(857) 999-0075
住所
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
KALV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
12.44 | 624.92M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.04 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.46 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.81 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
643.92 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
304.15 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-31 | 開始されました | JMP Securities | Mkt Outperform |
| 2025-01-07 | 開始されました | TD Cowen | Buy |
| 2024-12-18 | 開始されました | BofA Securities | Buy |
| 2020-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2019-07-29 | 開始されました | SVB Leerink | Outperform |
| 2019-03-20 | 開始されました | Needham | Buy |
| 2018-10-30 | 開始されました | Jefferies | Buy |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 開始されました | BTIG Research | Buy |
すべてを表示
Kalvista Pharmaceuticals Inc (KALV) 最新ニュース
KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union - BioSpace
KalVista Pharmaceuticals Announces Maintenance of Orphan Designa - GuruFocus
FDA approved six NMEs in July - biocentury.com
KalVista Pharmaceuticals Grants Stock Options to New Hires - AInvest
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 4, 2025 - BioSpace
Reversal Traders Monitor KalVista Pharmaceuticals Inc. for EntryFundamental Growth Stock Analysis Shows Strength - metal.it
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KALV Stock News - GuruFocus
Published on: 2025-08-04 07:21:19 - Jammu Links News
What are analysts’ price targets for KalVista Pharmaceuticals Inc. in the next 12 monthsBuild wealth steadily with proven stock picks - Jammu Links News
What institutional investors are buying KalVista Pharmaceuticals Inc. stockRapid wealth creation - Jammu Links News
Is KalVista Pharmaceuticals Inc. stock overvalued or undervaluedMaximize your portfolio’s earning power - Jammu Links News
What analysts say about KalVista Pharmaceuticals Inc. stockInvest confidently with actionable market data - Jammu Links News
What are the technical indicators suggesting about KalVista Pharmaceuticals Inc.Unstoppable investment returns - Jammu Links News
When is KalVista Pharmaceuticals Inc. stock expected to show significant growthAchieve consistent profits with expert strategies - Jammu Links News
What drives KalVista Pharmaceuticals Inc. stock priceConsistently profitable trades - Jammu Links News
KalVista Pharmaceuticals Inc. Stock Analysis and ForecastUnlock exclusive investment alerts - Jammu Links News
What is the risk reward ratio of investing in KalVista Pharmaceuticals Inc. stockAdvanced Screener Growth Plan For Every Investor - Jammu Links News
What are KalVista Pharmaceuticals Inc. company’s key revenue driversAI Powered Tracker That Work - Jammu Links News
KalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines Agency - MSN
Published on: 2025-07-29 19:52:44 - metal.it
What makes KalVista Pharmaceuticals Inc. stock price move sharplyTriple Return Setup With Risk Control Explained - beatles.ru
Sebetralstat recommended for EU approval for treating HAE attacks - Angioedema News
What is the dividend policy of KalVista Pharmaceuticals Inc. stockBreakthrough investment results - jammulinksnews.com
KalVista Pharmaceuticals Faces Downgrade Due to Shrinking Market and Oral Competitor Threat - AInvest
KalVista Pharmaceuticals Ekterly Faces A Shrinking Market And Oral Competitor Threat (Downgrade) - Seeking Alpha
Kalvista Pharmaceuticals shares rise 1.17% after-hours following positive CHMP opinion for sebetralstat. - AInvest
EMA’s CHMP adopts five orphans - BioCentury
What analysts say about KalVista Pharmaceuticals Inc. stock outlookPhenomenal capital gains - Jammu Links News
New medicines recommended for approval by EMA’s CHMP - The Pharma Letter
KalVista receives CHMP opinion recommending sebetralstat marketing authorization - TipRanks
KalVista, Biogen, Ionis get EU positive opinions for key drugs (KALV:NASDAQ) - Seeking Alpha
European regulator recommends approval of first oral HAE treatment - Investing.com
KalVista Pharma Announces Positive CHMP Opinion For Sebetralstat - Nasdaq
KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks - Business Wire
US FDA Cancer Reviewers Heading For The Exits, Potentially Impacting Review Timelines - insights.citeline.com
Is KalVista Pharmaceuticals Inc. a good long term investmentRapid return acceleration - jammulinksnews.com
Kalvista Pharmaceuticals Inc (KALV) 財務データ
収益
当期純利益
現金流量
EPS
0.59%
0.18%
大文字化:
|
ボリューム (24 時間):